Business Development

Our Platform

4 Major Verticals

Lanier 4 Verticals

About Lanier Biotherapeutics

Lanier Biotherapeutics was founded by combining the businesses of Biophtha and Abeome, to further develop an existing first-in-class biologics portfolio for specialty disease, with the ultimate goal of improving the way we survive, age, and live. Lanier targets four major verticals: Multi-functional Retina, Type 2 Inflammation, Dermatology, and Immuno Oncology. Lanier’s lead developments programs include LNR 653.1, a fully humanized anti-VEGF / IL-17A multifunctional antibody for the treatment of retinal neovascularization diseases and LNR 125.36, a fully humanized anti-IL25 monoclonal antibody for the treatment of Type 2 Inflammatory diseases.

Latest News

Oct 6, 2021

Newly Formed Lanier Biotherapeutics Enters into License Agreement with Alloy Therapeutics

Read more
July 9, 2021

Molecular Templates, Inc. Announces Dosing of First Subject in Phase 1 Study of MT-6402 in PD-L1-Positive Solid Tumors

Read more

Contact our business development team